Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

LATAM Radiopharmaceuticals Market by Type (CONTRAST REAGENTS, NUCLEAR REAGENTS) and by Application (DIAGNOSTICS, DRUG DISCOVERY DEVELOPMENT, RD): Global Opportunity Analysis and Industry Forecast, 2023-2032

A04508

Pages: NA

Charts: NA

Tables: NA

 Key Market Segments

  • By Type
    • CONTRAST REAGENTS
    • NUCLEAR REAGENTS
  • By Application
    • DIAGNOSTICS
    • DRUG DISCOVERY & DEVELOPMENT
    • R&D
  • By Region
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Almac Group
  • Biocad
  • Triad Isotopes
  • NURIX Pharmaceuticals
  • AUSPEC Pharmaceuticals
  • Amersham Health
  • McKesson Corporation
  • Arc Evolution Corp.
  • Mallinckrodt plc
  • Jubilant Life Sciences Ltd.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: LATAM RADIOPHARMACEUTICALS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. CONTRAST REAGENTS

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. NUCLEAR REAGENTS

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: LATAM RADIOPHARMACEUTICALS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. DIAGNOSTICS

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. DRUG DISCOVERY DEVELOPMENT

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. RD

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: LATAM RADIOPHARMACEUTICALS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S.

        • 6.2.5.1 Market size and forecast, type

        • 6.2.5.2 Market size and forecast, application

      • 6.2.6. Canada

        • 6.2.6.1 Market size and forecast, type

        • 6.2.6.2 Market size and forecast, application

      • 6.2.7. Mexico

        • 6.2.7.1 Market size and forecast, type

        • 6.2.7.2 Market size and forecast, application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France

        • 6.3.5.1 Market size and forecast, type

        • 6.3.5.2 Market size and forecast, application

      • 6.3.6. Germany

        • 6.3.6.1 Market size and forecast, type

        • 6.3.6.2 Market size and forecast, application

      • 6.3.7. Italy

        • 6.3.7.1 Market size and forecast, type

        • 6.3.7.2 Market size and forecast, application

      • 6.3.8. Spain

        • 6.3.8.1 Market size and forecast, type

        • 6.3.8.2 Market size and forecast, application

      • 6.3.9. UK

        • 6.3.9.1 Market size and forecast, type

        • 6.3.9.2 Market size and forecast, application

      • 6.3.10. Russia

        • 6.3.10.1 Market size and forecast, type

        • 6.3.10.2 Market size and forecast, application

      • 6.3.11. Rest Of Europe

        • 6.3.11.1 Market size and forecast, type

        • 6.3.11.2 Market size and forecast, application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China

        • 6.4.5.1 Market size and forecast, type

        • 6.4.5.2 Market size and forecast, application

      • 6.4.6. Japan

        • 6.4.6.1 Market size and forecast, type

        • 6.4.6.2 Market size and forecast, application

      • 6.4.7. India

        • 6.4.7.1 Market size and forecast, type

        • 6.4.7.2 Market size and forecast, application

      • 6.4.8. South Korea

        • 6.4.8.1 Market size and forecast, type

        • 6.4.8.2 Market size and forecast, application

      • 6.4.9. Australia

        • 6.4.9.1 Market size and forecast, type

        • 6.4.9.2 Market size and forecast, application

      • 6.4.10. Thailand

        • 6.4.10.1 Market size and forecast, type

        • 6.4.10.2 Market size and forecast, application

      • 6.4.11. Malaysia

        • 6.4.11.1 Market size and forecast, type

        • 6.4.11.2 Market size and forecast, application

      • 6.4.12. Indonesia

        • 6.4.12.1 Market size and forecast, type

        • 6.4.12.2 Market size and forecast, application

      • 6.4.13. Rest of Asia Pacific

        • 6.4.13.1 Market size and forecast, type

        • 6.4.13.2 Market size and forecast, application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil

        • 6.5.5.1 Market size and forecast, type

        • 6.5.5.2 Market size and forecast, application

      • 6.5.6. South Africa

        • 6.5.6.1 Market size and forecast, type

        • 6.5.6.2 Market size and forecast, application

      • 6.5.7. Saudi Arabia

        • 6.5.7.1 Market size and forecast, type

        • 6.5.7.2 Market size and forecast, application

      • 6.5.8. UAE

        • 6.5.8.1 Market size and forecast, type

        • 6.5.8.2 Market size and forecast, application

      • 6.5.9. Argentina

        • 6.5.9.1 Market size and forecast, type

        • 6.5.9.2 Market size and forecast, application

      • 6.5.10. Rest of LAMEA

        • 6.5.10.1 Market size and forecast, type

        • 6.5.10.2 Market size and forecast, application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Mallinckrodt Plc

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. NURIX Pharmaceuticals

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Amersham Health

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Jubilant Life Sciences Ltd.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Biocad

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Almac Group

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Triad Isotopes

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. McKesson Corporation

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. AUSPEC Pharmaceuticals

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Arc Evolution Corp.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL LATAM RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. LATAM RADIOPHARMACEUTICALS MARKET FOR CONTRAST REAGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. LATAM RADIOPHARMACEUTICALS MARKET FOR NUCLEAR REAGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL LATAM RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 5. LATAM RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. LATAM RADIOPHARMACEUTICALS MARKET FOR DRUG DISCOVERY DEVELOPMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. LATAM RADIOPHARMACEUTICALS MARKET FOR RD, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. LATAM RADIOPHARMACEUTICALS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA LATAM RADIOPHARMACEUTICALS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 12. U.S. LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 13. U.S. LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 14. CANADA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. CANADA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE LATAM RADIOPHARMACEUTICALS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. ITALY LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. ITALY LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. UK LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. UK LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC LATAM RADIOPHARMACEUTICALS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. CHINA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. CHINA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. INDIA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. INDIA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA LATAM RADIOPHARMACEUTICALS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. UAE LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. UAE LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA LATAM RADIOPHARMACEUTICALS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA LATAM RADIOPHARMACEUTICALS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. MALLINCKRODT PLC: KEY EXECUTIVES
  • TABLE 72. MALLINCKRODT PLC: COMPANY SNAPSHOT
  • TABLE 73. MALLINCKRODT PLC: OPERATING SEGMENTS
  • TABLE 74. MALLINCKRODT PLC: PRODUCT PORTFOLIO
  • TABLE 75. MALLINCKRODT PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. NURIX PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 77. NURIX PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 78. NURIX PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 79. NURIX PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 80. NURIX PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. AMERSHAM HEALTH: KEY EXECUTIVES
  • TABLE 82. AMERSHAM HEALTH: COMPANY SNAPSHOT
  • TABLE 83. AMERSHAM HEALTH: OPERATING SEGMENTS
  • TABLE 84. AMERSHAM HEALTH: PRODUCT PORTFOLIO
  • TABLE 85. AMERSHAM HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. JUBILANT LIFE SCIENCES LTD.: KEY EXECUTIVES
  • TABLE 87. JUBILANT LIFE SCIENCES LTD.: COMPANY SNAPSHOT
  • TABLE 88. JUBILANT LIFE SCIENCES LTD.: OPERATING SEGMENTS
  • TABLE 89. JUBILANT LIFE SCIENCES LTD.: PRODUCT PORTFOLIO
  • TABLE 90. JUBILANT LIFE SCIENCES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. BIOCAD: KEY EXECUTIVES
  • TABLE 92. BIOCAD: COMPANY SNAPSHOT
  • TABLE 93. BIOCAD: OPERATING SEGMENTS
  • TABLE 94. BIOCAD: PRODUCT PORTFOLIO
  • TABLE 95. BIOCAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. ALMAC GROUP: KEY EXECUTIVES
  • TABLE 97. ALMAC GROUP: COMPANY SNAPSHOT
  • TABLE 98. ALMAC GROUP: OPERATING SEGMENTS
  • TABLE 99. ALMAC GROUP: PRODUCT PORTFOLIO
  • TABLE 100. ALMAC GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. TRIAD ISOTOPES: KEY EXECUTIVES
  • TABLE 102. TRIAD ISOTOPES: COMPANY SNAPSHOT
  • TABLE 103. TRIAD ISOTOPES: OPERATING SEGMENTS
  • TABLE 104. TRIAD ISOTOPES: PRODUCT PORTFOLIO
  • TABLE 105. TRIAD ISOTOPES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. MCKESSON CORPORATION: KEY EXECUTIVES
  • TABLE 107. MCKESSON CORPORATION: COMPANY SNAPSHOT
  • TABLE 108. MCKESSON CORPORATION: OPERATING SEGMENTS
  • TABLE 109. MCKESSON CORPORATION: PRODUCT PORTFOLIO
  • TABLE 110. MCKESSON CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. AUSPEC PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 112. AUSPEC PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 113. AUSPEC PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 114. AUSPEC PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 115. AUSPEC PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. ARC EVOLUTION CORP.: KEY EXECUTIVES
  • TABLE 117. ARC EVOLUTION CORP.: COMPANY SNAPSHOT
  • TABLE 118. ARC EVOLUTION CORP.: OPERATING SEGMENTS
  • TABLE 119. ARC EVOLUTION CORP.: PRODUCT PORTFOLIO
  • TABLE 120. ARC EVOLUTION CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL LATAM RADIOPHARMACEUTICALS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL LATAM RADIOPHARMACEUTICALS MARKET
  • FIGURE 3. SEGMENTATION LATAM RADIOPHARMACEUTICALS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN LATAM RADIOPHARMACEUTICALS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLATAM RADIOPHARMACEUTICALS MARKET
  • FIGURE 11. LATAM RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY TYPE
  • FIGURE 12. LATAM RADIOPHARMACEUTICALS MARKET FOR CONTRAST REAGENTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. LATAM RADIOPHARMACEUTICALS MARKET FOR NUCLEAR REAGENTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. LATAM RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 15. LATAM RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. LATAM RADIOPHARMACEUTICALS MARKET FOR DRUG DISCOVERY DEVELOPMENT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. LATAM RADIOPHARMACEUTICALS MARKET FOR RD, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: LATAM RADIOPHARMACEUTICALS MARKET
  • FIGURE 24. TOP PLAYER POSITIONING,2022
  • FIGURE 25. MALLINCKRODT PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 26. MALLINCKRODT PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 27. MALLINCKRODT PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 28. NURIX PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. NURIX PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. NURIX PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. AMERSHAM HEALTH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. AMERSHAM HEALTH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. AMERSHAM HEALTH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. JUBILANT LIFE SCIENCES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. JUBILANT LIFE SCIENCES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. JUBILANT LIFE SCIENCES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. BIOCAD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. BIOCAD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. BIOCAD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. ALMAC GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. ALMAC GROUP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. ALMAC GROUP: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. TRIAD ISOTOPES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. TRIAD ISOTOPES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. TRIAD ISOTOPES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. MCKESSON CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. MCKESSON CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. MCKESSON CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. AUSPEC PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. AUSPEC PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. AUSPEC PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. ARC EVOLUTION CORP.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. ARC EVOLUTION CORP.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. ARC EVOLUTION CORP.: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
LATAM Radiopharmaceuticals Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved